Abstract:
Summary.
Introduction. Ischemic heart disease is one of the most
widespread cardiovascular diseases. In Republic of Moldova
the total number of patients with ischemic heart disease is
30-40 thousand per 1 million population and is observed
more of working age with important social value.
Materials and method. An open randomized clinical
trial involving 139 patients with chronic heart failure (107
men and 32 women) aged 37 to 81 years: 111 patients had
angina pectoris of stable effort from different functional
classes, and 28 – unstable angina pectoris, which include:
basic treatment n = 43; basic treatment + meldonium
(non-infarct) n = 52; basic treatment + meldonium (post-infarct) n = 35; basic treatment + meldonium, (aggravated) n
= 9. Study groups were compared according to the frequency of using background (basic) drugs and meldonium. Statistical processing of the results was carried out in Statistics
Software Package 9.0.
Results. During the treatment, the increase of the nitric
oxide level was registered even from the discharge stage, and
in the second group being approximately at the same level as
the initial stage. At the 3-month, nitric oxide level reached the
normal level. There is an improvement of the endothelial dysfunction by the significant increase of the nitric oxide under
the treatment at 6 months (in group I – 87.26±4.3 µM/L (p =
0.01), in group II – 95.33±10.85 µM/L).
Conclusions. The inclusion of meldonium in the complex treatment of patients with stable angina increases the
clinical efficacy of basic pharmacotherapy when prescribing
meldonium, mainly due to increased antianginal actions.
